Epoetin alfa: new directions in orthopedic surgery.
The introduction of autologous blood (AB) donation programs has led to a decrease in the number of orthopedic surgery patients exposed to allogeneic blood, although there is still room for improvement. For example, some patients may not be able to donate sufficient AB to meet their expected blood requirements. Virtually all nonanemic patients can donate 3 AB units prior to orthopedic surgery before further AB donation is limited by the development of anemia. In preliminary studies, the administration of epoetin alfa (150 IU/kg subcutaneously (s.c.) on alternate days; six doses) following the donation of 3 AB units reversed phlebotomy-induced anemia and enabled a further 2 units of AB to be collected. The ability of this therapeutic approach to increase AB procurement and reduce allogeneic blood requirements is being investigated in an ongoing, placebo-controlled study. An alternative approach may be to combine perisurgical treatment with epoetin alfa and normovolemic hemodilution (NVHD) prior to orthopedic surgery. Although such studies have yet to be initiated, they may demonstrate a reduction in allogeneic blood exposure in patients unable to donate AB prior to orthopedic surgery, a group of patients traditionally at high risk of exposure to allogeneic blood.
Beris
P
P
Hôpital Cantonal, University of Geneva, Switzerland.
D000740:Anemia / Q000517:prevention & control; D016063:Blood Loss, Surgical; D001804:Blood Transfusion, Autologous; D001810:Blood Volume; D002986:Clinical Trials as Topic; D000068817:Epoetin Alfa; D004920:Erythropoiesis; D004921:Erythropoietin / Q000008:administration & dosage / Q000494:pharmacology*; D006438:Hemodilution; D006801:Humans; D009985:Orthopedics / Q000639:trends*; D011292:Premedication; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa